Key Points
- Insider sale: Equillium COO Christine Zedelmayer sold 181,219 shares on March 9 at $2.00 each (~$362,438), leaving her with 62,586 shares — a 74.33% reduction in her position.
- Ongoing liquidation: Zedelmayer has repeatedly sold large blocks of EQ stock since December (including 185,937 shares on Feb 19 and 100,000 on Dec 23), indicating sustained insider selling over several months.
- Market and analyst context: EQ trades around $2.00 with a $122M market cap and thin recent volume, and analysts carry a consensus "Hold" rating with a $3.00 target amid mixed opinions.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 181,219 shares of Equillium stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $2.00, for a total value of $362,438.00. Following the completion of the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $125,172. This represents a 74.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Christine Zedelmayer also recently made the following trade(s):
- On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The shares were sold at an average price of $1.76, for a total value of $327,249.12.
- On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total value of $150,000.00.
- On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The stock was sold at an average price of $1.31, for a total value of $15,589.00.
- On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total value of $31,897.36.
Equillium Stock Performance
Equillium stock traded up $0.01 during midday trading on Thursday, reaching $2.00. The stock had a trading volume of 38,345 shares, compared to its average volume of 460,159. The stock has a market capitalization of $122.03 million, a P/E ratio of -3.21 and a beta of 1.81. The firm's fifty day simple moving average is $1.51 and its 200-day simple moving average is $1.41. Equillium, Inc. has a 1-year low of $0.27 and a 1-year high of $2.35.
Institutional Trading of Equillium
A number of hedge funds have recently made changes to their positions in EQ. Virtu Financial LLC boosted its stake in shares of Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock worth $34,000 after acquiring an additional 13,591 shares during the period. Millennium Management LLC bought a new stake in Equillium in the 3rd quarter valued at $35,000. Persistent Asset Partners Ltd bought a new stake in Equillium in the 3rd quarter valued at $99,000. Royal Bank of Canada acquired a new stake in Equillium during the 4th quarter valued at $124,000. Finally, Boothbay Fund Management LLC acquired a new stake in Equillium during the 3rd quarter valued at $174,000. 27.05% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have recently issued reports on EQ shares. Zacks Research upgraded shares of Equillium to a "hold" rating in a report on Thursday, February 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Equillium in a report on Monday, December 29th. Stifel Nicolaus began coverage on shares of Equillium in a research report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 target price for the company. Finally, Wall Street Zen lowered shares of Equillium from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $3.00.
Read Our Latest Report on Equillium
About Equillium
(
Get Free Report)
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
